ArticlePloS one2026
HIV-1 genetic diversity and reverse transcriptase resistance mutations in Benin before dolutegravir era, West Africa.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benin adopted the World Health Organization's (WHO) "Test and Treat" recommendation in 2016 and, since 2019, has updated this protocol by including dolutegravir (DTG) as the preferred first-line treatment. Study aimed to assess the prevalence of virological failure (VL > 3log copies/mL) and review genetic diversity and antiretroviral resistance mutations in patients on antiretroviral treatment for at least 12 months before dolutegravir Era in Benin. Cross-sectional study included patient plasmas from antiretroviral treatment sites nationwide. Viral load was performed in National Reference Laboratory of Health Program Fighting Against AIDS using the Cobas® 5800 HIV-1 assay. For plasmas those VL above 1000 copies/mL, nested PCR were done along the entire protease and part of reverse transcriptase. The DNA obtained by the Sanger method was used to determine the subtypes of HIV-1 after editing with DNASTAR SeqMan Pro™ and alignment with ClustalW2 version 2.1. Phylogenetic trees were constructed by the Neighbor-Joining method and recombinants were investigated by bootscanning with Seaview software version 2.1. DNA was subjected to the Stanford University Antiretroviral Resistance Mutation Interpretation Algorithm (https://hivdb.stanford.edu/) to identify the positions of drug-associated resistance mutations. (178/253; 70.35%) of the samples were correctly amplified and sequenced. CRF02_AG (n = 104) was the predominant strain observed followed by CRF06_cpx (n = 21), G (n = 5), CRF43_02G (n = 2), CRF37_cpx (n = 2), A1 (n = 1) and unique recombinant forms (URFs) (n = 34) among the 169 samples sequenced on entire protease combined with part of the reverse transcriptase. (164/178; 92.1%), (141/178; 79.2%), (160/178; 89.9%) and (7/169; 4.1%) patients carried at least one drug resistance associated to NRTIs, NNRTIs and PIs respectively. M184I/V, TAMSI: (M41L, L210W, T215Y) and TAMSII: (D67N, K70R, K219Q/E, T215I/V) represented (71.3%), (21.9%), (35.4%) respectively. K103N/S was the most preponderant mutations encountered with a proportion of 64.6% followed by V179E (21.3%), P225H (20.2%), V108I (19.1%), Y181C (16.3%), A98G (15.2%), V106I/M/A (10.1%). I84V (1.8%) mutation was the major associated PIs encountered followed by L90M, V82A, M46I each encountered twice (1.2%) and I47A, V32I, I54V, G48A, each encountered once (0.6%). Study shows a high genetic diversity with the presence of new strains and underlines the need to regularly review data on genetic diversity and resistance among patients receiving antiretroviral therapy in the country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.